Strainprint™ Technologies Ltd. ("Strainprint") Solidifies Innovation Leadership with Invitation to the MaRS Health Venture Services Program

Strainprint™ and MaRS (CNW Group/Strainprint Technologies Ltd.)

TORONTO, Sept. 11, 2017 /CNW/ - Strainprint^TM, the leader in cannabis data collection and strain efficacy reporting, is pleased to announce that it is the first cannabis-focused technology company to be invited to join the MaRS Health Venture Services program.  MaRS is the world's largest urban innovation hub and its Health Venture Services program supports leaders in innovation in health sciences and technology.  Membership in the program gives Strainprint premium access to government resources, market intelligence and a world-class partner network.

"We are honoured to join the MaRS Health Venture Services program, alongside other high-impact companies developing breakthroughs in their field.  It is validation of our commitment to innovation and recognition of the importance of data and analytics to legitimize the cannabis industry," said Dave Berg, Strainprint Chief Technology Officer.

This comes exactly as Strainprint releases version 1.4.3 of its revolutionary mobile outcomes tracking app, the 11th major product update since it launched in March 2017.  Version 1.4.3 is optimized for Apple's next generation iPhone and is fully compatible with Apple's upcoming iOS 11 operating system.  This latest version brings over 60 new features and A.I. improvements to patient users across Canada and the U.S., including:

• Configurable feedback intervals for each ingestion method;
• Improved dosing accuracy with ability to specify cannabis weight in smoke and vape ingestion methods;
• Preventative tracking, which can be combined with other tracking sessions;
• New conditions/symptoms, including obsessive compulsive disorder, herniated disc, and neuropathic conditions and symptoms, plus nerve pain, restlessness, irritability, compulsive behaviour, challenge concentrating, numbness/tingling, arm or leg pain, and weakness; and
• Advanced ingestion methods such as transdermal patches, topicals, sprays, Dabs and Bubblers, plus smart-configuration for over 200 popular pre-packed electronic pen vapes;

"Our patients are active and engaged with us in tracking their medical cannabis therapy.  In fact, many of our latest product advancements were driven by positive customer feedback and that pushes us to innovate daily." explained Evan Karasick, Strainprint Chief Product Officer.

Strainprint's leading data collection and analytics platform helps thousands of patients to learn which strains work best for them and, in the process, has become the largest and most detailed longitudinal study of cannabis strain efficacy in the world.  Strainprint's anonymous, aggregated data is used by doctors, producers, retailers, researchers and governments throughout North America.

The Strainprint mobile app is available today for both iOS and Android users.

About Strainprint^TM:

Founded in Toronto in 2016, Strainprint^TM Technologies Ltd. is a Toronto-based software company providing enterprise grade analytics and consumer solutions for the medical cannabis industry.  Strainprint manages the gathering and analysis of real-time cannabis consumption data and ranks specific strain efficacy against conditions and related symptoms.  Strainprint^TM data supports cannabis researchers globally and provides advanced intelligence to licensed producers to optimize grow operations and to clinics to improve treatment recommendations.  For more information visit www.strainprint.ca. facebook, twitter, linkedin

SOURCE Strainprint Technologies Ltd.

Media Contact: Jessica Moran, Strainprint™ Technologies Ltd., [email protected]